LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.

Erika Hamilton,Camille Catherine Jackson,Ramez N. Eskander,Floor Jenniskens Backes,Vicky Makker,Fernanda Musa,Alexander B. Olawaiye,Jill Alldredge,Bhavana Pothuri,Angeles Alvarez Secord,Nicole Concin,Antonio González-Martín,Jowell Go,Kenton Wride,Denise M. Lepley,T. Cameron,Manish R. Patel

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.

2021

Erika Hamilton
Camille Catherine Jackson
Ramez N. Eskander
Floor Jenniskens Backes
Vicky Makker
Fernanda Musa
Alexander B. Olawaiye
Jill Alldredge
Bhavana Pothuri
Angeles Alvarez Secord
Nicole Concin
Antonio González-Martín
Jowell Go
Kenton Wride
Denise M. Lepley
T. Cameron
Manish R. Patel

5538Background: The phase (Ph) 1b part of LIO-1 (NCT04042116; ENGOT-GYN3/AGO/LIO) assessed the oral antiangiogenic, multikinase inhibitor lucitanib + immune checkpoint inhibitor nivolumab, confirmi...

Keywords:

Nivolumab
Medicine
Internal medicine
Cohort
Oncology
Ovarian cancer
in patient
multikinase inhibitor
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations